OBJECTIVES: We sought to examine the association between the metabolic syndrome (MetS) (defined both by the 2001 National Cholesterol Educational Program Adult Treatment Panel III [ATP-III] definition and the American Heart Association/National Heart, Lung and Blood Institute [AHA/NHLBI] revision incorporating the lower threshold for impaired fasting glucose [IFG]) and early-onset coronary artery disease (CAD). BACKGROUND: The impact of MetS on premature CAD has not been studied extensively. Lowering the threshold to define the IFG component (from 110 to 100 mg/dl) and the value of the syndrome as a whole versus its individual components are subjects of intense debate. METHODS: We performed a case-control study with 393 early-onset CAD subjects (acute myocardial infarction, angina with > or =50% stenosis, or coronary revascularization) in men under age 46 years or women under age 56 years and 393 control subjects individually matched for gender, age, and race/ethnicity. RESULTS: By conditional logistic regression, presence of ATP-III MetS without diabetes (adjusted odds ratio [adj-OR] 4.9; 95% confidence interval [CI] 3.4 to 8.0) and with diabetes (adj-OR 8.0, 95% CI 4.39 to 14.6) was a strong independent determinant of early-onset CAD. Using the AHA/NHLBI revision, these ORs became slightly stronger. However, neither definition of MetS remained significantly associated with early-onset CAD in multivariate models adjusting for individual components. CONCLUSIONS: The presence of MetS imparts a high risk of early-onset clinical CAD, but the prognostic information associated with the syndrome is not greater than the sum of its parts.
OBJECTIVES: We sought to examine the association between the metabolic syndrome (MetS) (defined both by the 2001 National Cholesterol Educational Program Adult Treatment Panel III [ATP-III] definition and the American Heart Association/National Heart, Lung and Blood Institute [AHA/NHLBI] revision incorporating the lower threshold for impaired fasting glucose [IFG]) and early-onset coronary artery disease (CAD). BACKGROUND: The impact of MetS on premature CAD has not been studied extensively. Lowering the threshold to define the IFG component (from 110 to 100 mg/dl) and the value of the syndrome as a whole versus its individual components are subjects of intense debate. METHODS: We performed a case-control study with 393 early-onset CAD subjects (acute myocardial infarction, angina with > or =50% stenosis, or coronary revascularization) in men under age 46 years or women under age 56 years and 393 control subjects individually matched for gender, age, and race/ethnicity. RESULTS: By conditional logistic regression, presence of ATP-III MetS without diabetes (adjusted odds ratio [adj-OR] 4.9; 95% confidence interval [CI] 3.4 to 8.0) and with diabetes (adj-OR 8.0, 95% CI 4.39 to 14.6) was a strong independent determinant of early-onset CAD. Using the AHA/NHLBI revision, these ORs became slightly stronger. However, neither definition of MetS remained significantly associated with early-onset CAD in multivariate models adjusting for individual components. CONCLUSIONS: The presence of MetS imparts a high risk of early-onset clinical CAD, but the prognostic information associated with the syndrome is not greater than the sum of its parts.
Authors: Themistocles L Assimes; Joshua W Knowles; James R Priest; Analabha Basu; Astrid Borchert; Kelly A Volcik; Megan L Grove; Holly K Tabor; Audrey Southwick; Raymond Tabibiazar; Steve Sidney; Eric Boerwinkle; Alan S Go; Carlos Iribarren; Mark A Hlatky; Stephen P Fortmann; Richard M Myers; Hartmut Kuhn; Neil Risch; Thomas Quertermous Journal: Atherosclerosis Date: 2007-10-23 Impact factor: 5.162
Authors: Fouad Zakharia; Analabha Basu; Devin Absher; Themistocles L Assimes; Alan S Go; Mark A Hlatky; Carlos Iribarren; Joshua W Knowles; Jun Li; Balasubramanian Narasimhan; Steven Sidney; Audrey Southwick; Richard M Myers; Thomas Quertermous; Neil Risch; Hua Tang Journal: Genome Biol Date: 2009-12-22 Impact factor: 13.583
Authors: Jean Dallongeville; Carlos Iribarren; Jean Ferrières; Liisa Lyon; Alun Evans; Alan S Go; Dominique Arveiler; Stephen P Fortmann; Pierre Ducimetière; Mark A Hlatky; Philippe Amouyel; Audrey Southwick; Thomas Quertermous; Aline Meirhaeghe Journal: PPAR Res Date: 2009-12-01 Impact factor: 4.964
Authors: Themistocles L Assimes; Joshua W Knowles; Analabha Basu; Carlos Iribarren; Audrey Southwick; Hua Tang; Devin Absher; Jun Li; Joan M Fair; Geoffrey D Rubin; Stephen Sidney; Stephen P Fortmann; Alan S Go; Mark A Hlatky; Richard M Myers; Neil Risch; Thomas Quertermous Journal: Hum Mol Genet Date: 2008-04-28 Impact factor: 6.150
Authors: Themistocles L Assimes; Joshua W Knowles; James R Priest; Analabha Basu; Kelly A Volcik; Audrey Southwick; Holly K Tabor; Jaana Hartiala; Hooman Allayee; Megan L Grove; Raymond Tabibiazar; Stephen Sidney; Stephen P Fortmann; Alan Go; Mark Hlatky; Carlos Iribarren; Eric Boerwinkle; Richard Myers; Neil Risch; Thomas Quertermous Journal: Hum Genet Date: 2008-03-28 Impact factor: 4.132